<DOC>
	<DOCNO>NCT01331018</DOCNO>
	<brief_summary>This pilot trial access toxicity efficacy infusion gene modify cell patient Fanconi anemia ( FA ) . Infusion autologous patient blood stem cell correct laboratory introduction normal gene may improve blood count patient FA .</brief_summary>
	<brief_title>Gene Therapy Fanconi Anemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine safety lentiviral gene transfer patient Fanconi anemia complementation group A ( FANCA ) . SECONDARY OBJECTIVES : I . To determine feasibility efficacy filgrastim ( G-CSF ) plerixafor mobilization FA patient . II . To determine feasibility efficacy lineage depletion bone marrow mobilize apheresis product . III . To determine transduction efficiency human FA patient hematopoietic progenitor cell transduce clinical grade lentiviral vector encode gene Fanconi anemia complementation group A. IV . To determine gene transfer use clinical grade vector result phenotypic correction gene modify cell vitro assay . V. To determine infusion FANCA gene-modified cell result engraftment persistence gene-modified cell improvement blood count FA patient . OUTLINE : STEM CELL MOBILIZATION : Patients receive filgrastim subcutaneously ( SC ) twice daily ( BID ) day 1-6 . Patients receive plerixafor SC daily ( QD ) day 4-6 . BONE MARROW HARVEST FOR CELL COLLECTION : Patients inadequate PBSC count undergo bone marrow harvest collection stem/progenitor cell . REINFUSION : Patients receive methylprednisolone intravenously ( IV ) prednisone orally ( PO ) day -1 7 undergo reinfusion genetically modify hematopoietic progenitor cell day 0 . After completion study treatment , patient follow periodically 15 year .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Cortisone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Cortisone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>FA demonstrate positive test increase sensitivity chromosomal breakage mitomycin C diepoxybutane perform Clinical Laboratory Improvement Amendments ( CLIA ) College American Pathologists ( CAP ) approve laboratory FA complementation group A determine somatic cell hybrid , molecular characterization , western blot analysis , acquisition mitomycin C resistance vitro lentiviral transduction vector bear complementary deoxyribonucleic acid ( cDNA ) Fanconi complementation group A Bone marrow analysis demonstrate normal cytogenetics , 5 % cell single clonal abnormality fluorescence situ hybridization ( FISH ) myelodysplastic syndrome ( MDS ) panel within 3 month stem cell collection Signed informed consent patient legally authorize representative Absolute neutrophil count &gt; = 0.5 x 10^9/L Hemoglobin &gt; = 8 g/dL Platelet count &gt; = 20 x 10^9/L able achieve platelet count &gt; = 50 x 10^9/L transfusion support Adequate hepatic function aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 5 x upper limit normal ( ULN ) Adequate renal function creatinine ( Cre ) = &lt; 1.5 ; great , glomerular filtration rate ( GFR ) &gt; 60 mL/min/1.73 m^2 calculate Modification Diet Renal Disease equation Adequate pulmonary function correct diffusion capacity carbon monoxide ( DLCO ) &gt; 50 % study perform For subject &lt; 17 year age , Modified Lansky PlayPerformance Score &gt; = 70 % ; subject 17 older , Karnofsky score &gt; = 70 % Nonhematopoietic malignancy expect survival less 2 year Myelodysplastic syndrome define World Health Organization ( WHO ) criteria Acute myeloid leukemia define WHO criteria Pregnancy lactation ; female childbearing potential male admit study advise study procedure study drug may teratogenic , require take adequate measure prevent conception duration study Concurrent enrollment study use investigational drug Physical emotional status would prevent informed consent , protocol compliance , adequate followup Patients human leukocyte antigen ( HLA ) match sibling donor bone marrow transplant actively pursue eligible study determine sibling donor available stem cell transplant feasible time patient might study No patient include study alternative clinically indicate HLA match sibling donor stem cell transplant If HLA match sibling donor identify , stem cell marrow collection feasible ( e.g. , donor utero , newborn cord blood collect , unable undergo donation procedure ill health ) , patient may include study discretion investigator Significant associate disease include documented human immunodeficiency virus ( HIV ) infection , uncontrolled hypertension ( diastolic blood pressure &gt; 95 % ile age ) , unstable angina , congestive heart failure ( &gt; New York Heart Association [ NYHA ] class II ) , poorly control diabetes ( hemoglobin A1c [ Hgb A1c ] &gt; 7 % ) , coronary angioplasty within 6 month , myocardial infarction within last 6 month , uncontrolled atrial ventricular cardiac arrhythmia , abnormal coagulation , persistent abnormal urinalysis reflect intrinsic renal disease Active ongoing viral , bacterial , fungal infection</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>